CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals, Inc., an oncology focused specialty pharmaceutical company, announced today that the first patient has been treated in a phase I/II investigator-initiated clinical study of romidepsin in combination with bortezomib to treat patients with relapsed/refractory multiple myeloma. The study is being conducted at the Peter MacCallum Cancer Centre in Melbourne, Australia.
